If orphan drugs and rare diseases were a theme of 2013's biotech bull market, then today's $700 million deal between Alnylam (NASDAQ:ALNY) and Sanofi (NYSE:SNY) is a sign it isn't slowing down anytime soon.
Alynlam wasn't just on the receiving end. It went out and acquired fellow RNAi specialist Sirna Therapeutics from Merck (NYSE:MRK) for just a fraction of what the Big Pharma paid for it in 2006.

In this video, Motley Fool health-care analyst David Williamson discusses the specifics of the deals, what Sanofi is gaining, why the market loves Alnylam, and why 2015, with half a dozen proof-of-concept trials reporting, will be a big year for the stock.

David Williamson owns shares of Merck. Follow David on Twitter: @MotleyDavid.

The Motley Fool recommends Alnylam Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.